Papers
Research literature with structured metadata.
Trials
Registered studies by status, phase, and compound.
Topics
Indications and themes psychedelics are researched for.
Compounds
Evidence across molecules with rich data.
Countries
Regulation, access, and research activity by region.
Stakeholders
Organizations shaping the space across research, policy, and funding.
People
Investigators, clinicians, and authors with mapped output.
Courses
Training programs and certifications across modalities.
Events
Conferences, workshops, and convenings by date and focus.
Results
Compare outcome data across trials and publications.
Research recaps
Monthly evidence summaries with key takeaways.
Map of research
Landscape view of trials, compounds, and outcomes.
Newsletter
Weekly or daily updates on trials, publications, analysis, and more.
Research Groups
Worldwide map of psychedelic research centres by region.
Road to Access
Science, regulation, and economics on the path to patient access.
Research Network
Interactive co-authorship map of psychedelic researchers.
Top papers
Find needles in the haystack of psychedelic research per topic.
Two naturalistic prospective studies in adults with severe ADHD symptoms found that psychedelic microdosing was associated with improved emotion regulation and a reduction in ADHD symptom severity over four weeks, with a persistent benefit on expressive suppression when compared with controls and conventional medication. There was no robust evidence that microdosing improved empathy.
The study found that both the Arabic General Health Questionnaire (AGHQ) and the SRQ‑20 are valid screens for ICD‑10 psychiatric disorders in an Arab community in Al Ain (AGHQ: sensitivity 86%, specificity 85%, AUC 0.93; SRQ‑20: sensitivity 83%, specificity 83%, AUC 0.90), with the AGHQ performing significantly better overall, especially in males and those under 30. The abstract appears unrelated to the paper’s title on MDMA and sexual function.